Khatri Wajahat, Chung Hyun Woo, Werner Rudolf A, Leal Jeffrey P, Pienta Kenneth J, Lodge Martin A, Gorin Michael A, Pomper Martin G, Rowe Steven P
The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Department of Nuclear Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul 05030, Korea.
Diagnostics (Basel). 2021 Apr 7;11(4):665. doi: 10.3390/diagnostics11040665.
Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) is emerging as an important modality for imaging patients with prostate cancer (PCa). As with any imaging modality, indeterminate findings will arise. The PSMA reporting and data system (PSMA-RADS) version 1.0 codifies indeterminate soft tissue findings with the PSMA-RADS-3A moniker. We investigated the role of point-spread function (PSF) reconstructions on categorization of PSMA-RADS-3A lesions.
This was a post hoc analysis of an institutional review board approved prospective trial. Around 60 min after the administration of 333 MBq (9 mCi) of PSMA-targeted F-DCFPyL, patients underwent PET/computed tomography (CT) acquisitions from the mid-thighs to the skull vertex. The PET data were reconstructed with and without PSF. Scans were categorized according to PSMA-RADS version 1.0, and all PSMA-RADS-3A lesions on non-PSF images were re-evaluated to determine if any could be re-categorized as PSMA-RADS-4. The maximum standardized uptake values (SUVs) of the lesions, mean SUVs of blood pool, and the ratios of those values were determined.
A total of 171 PSMA-RADS-3A lesions were identified in 30 patients for whom both PSF reconstructions and cross-sectional imaging follow-up were available. A total of 13/171 (7.6%) were re-categorized as PSMA-RADS-4 lesions with PSF reconstructions. A total of 112/171 (65.5%) were found on follow-up to be true positive for PCa, with all 13 of the re-categorized lesions being true positive on follow-up. The lesions that were re-categorized trended towards having higher SUV-lesion and SUV-lesion/SUV-blood-pool metrics, although these relationships were not statistically significant.
The use of PSF reconstructions for F-DCFPyL PET can allow the appropriate re-categorization of a small number of indeterminate PSMA-RADS-3A soft tissue lesions as more definitive PSMA-RADS-4 lesions. The routine use of PSF reconstructions for PSMA-targeted PET may be of value at those sites that utilize this technology.
前列腺特异性膜抗原(PSMA)正电子发射断层扫描(PET)正逐渐成为前列腺癌(PCa)患者成像的重要手段。与任何成像手段一样,会出现不确定的结果。PSMA报告和数据系统(PSMA-RADS)1.0版将不确定的软组织结果编码为PSMA-RADS-3A。我们研究了点扩散函数(PSF)重建在PSMA-RADS-3A病变分类中的作用。
这是一项对机构审查委员会批准的前瞻性试验的事后分析。在给予333 MBq(9 mCi)的PSMA靶向F-DCFPyL后约60分钟,患者接受从大腿中部到颅顶的PET/计算机断层扫描(CT)采集。PET数据在有和没有PSF的情况下进行重建。扫描根据PSMA-RADS 1.0版进行分类,对非PSF图像上所有的PSMA-RADS-3A病变进行重新评估,以确定是否有任何病变可以重新分类为PSMA-RADS-4。确定病变的最大标准化摄取值(SUV)、血池的平均SUV以及这些值的比率。
在30例患者中总共识别出171个PSMA-RADS-3A病变,这些患者同时有PSF重建和横断面成像随访数据。通过PSF重建,总共13/171(7.6%)个病变被重新分类为PSMA-RADS-4病变。随访发现总共112/171(65.5%)个病变为PCa真阳性,所有13个重新分类的病变在随访中均为真阳性。重新分类的病变倾向于具有更高的SUV-病变和SUV-病变/SUV-血池指标,尽管这些关系无统计学意义。
对F-DCFPyL PET使用PSF重建可以将少数不确定的PSMA-RADS-3A软组织病变适当重新分类为更明确的PSMA-RADS-4病变。在使用该技术的部位,对PSMA靶向PET常规使用PSF重建可能具有价值。